Advertisement
Advertisement
NOTV
Inotiv, Inc. Common Stock
0.30
USDSponsored
-0.01
-3.21%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
0.31
0.00
+1.59%
NOTV Earnings Reports
Positive Surprise Ratio
NOTV beat 12 of 21 last estimates.
57%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$127.24M
/-$0.64
Implied change from Q1 26 (Revenue/ EPS)
+5.26%
/-22.89%
Implied change from Q2 25 (Revenue/ EPS)
+2.34%
/+45.45%
Inotiv, Inc. Common Stock earnings per share and revenue
On Feb 09, 2026, NOTV reported earnings of -0.83 USD per share (EPS) for Q1 26, missing the estimate of -0.65 USD, resulting in a -27.14% surprise. Revenue reached 120.88 million, compared to an expected 123.33 million, with a -1.98% difference. The market reacted with a -13.63% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.64 USD, with revenue projected to reach 127.24 million USD, implying an decrease of -22.89% EPS, and increase of 5.26% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Inotiv, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Inotiv, Inc. Common Stock reported EPS of -$0.83, missing estimates by -27.14%, and revenue of $120.88M, -1.98% below expectations.
How did the market react to Inotiv, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -13.63%, changed from $0.42 before the earnings release to $0.36 the day after.
When is Inotiv, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Inotiv, Inc. Common Stock's next earnings report?
Based on 5
analysts, Inotiv, Inc. Common Stock is expected to report EPS of -$0.64 and revenue of $127.24M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement